Shuyun Hou1, Meixiang Sang2, Lianmei Zhao2, Ran Hou3, Baoen Shan4. 1. Department of Immunology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China; Research Center, The Fourth Hospital of Hebei Medical University, Jiankang Road 12th, Shijiazhuang 050017, Hebei, People's Republic of China. 2. Research Center, The Fourth Hospital of Hebei Medical University, Jiankang Road 12th, Shijiazhuang 050017, Hebei, People's Republic of China. 3. Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China. 4. Research Center, The Fourth Hospital of Hebei Medical University, Jiankang Road 12th, Shijiazhuang 050017, Hebei, People's Republic of China. Electronic address: baoenshan1962@hotmail.com.
Abstract
BACKGROUND: Our study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer. METHODS: Reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated. We examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines. RESULT: Proteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively. MAGE-C1 and MAGE-C2 expressions were positively associated with high tumor grade and reduced recurrence-free survival; MAGE-C2 expression was also associated with tumor embolus and histologic type. 5-aza-CdR treatment alone could induce expression of MAGE-C2, whereas trichostatin A was able to synergistically enhance 5-aza-CdR-mediated MAGE-C2 transcription. CONCLUSIONS: MAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.
BACKGROUND: Our study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer. METHODS: Reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated. We examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines. RESULT: Proteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively. MAGE-C1 and MAGE-C2 expressions were positively associated with high tumor grade and reduced recurrence-free survival; MAGE-C2 expression was also associated with tumor embolus and histologic type. 5-aza-CdR treatment alone could induce expression of MAGE-C2, whereas trichostatin A was able to synergistically enhance 5-aza-CdR-mediated MAGE-C2 transcription. CONCLUSIONS:MAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.
Authors: Stefan Hartmann; Leonie Zwick; Mario J J Scheurer; Andreas R Fuchs; Roman C Brands; Axel Seher; Hartmut Böhm; Alexander C Kübler; Urs D A Müller-Richter Journal: Clin Oral Investig Date: 2017-10-15 Impact factor: 3.573
Authors: Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts Journal: J Biol Chem Date: 2020-09-13 Impact factor: 5.157
Authors: Heather K Beasley; Sarrah E Widatalla; Diva S Whalen; Stephen D Williams; Olga Y Korolkova; Clementine Namba; Siddharth Pratap; Josiah Ochieng; Amos M Sakwe Journal: Front Endocrinol (Lausanne) Date: 2022-03-10 Impact factor: 5.555